Imiquimod induces skin inflammation in humanized BRGSF mice with limited human immune cell activity

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/36800344

Research summary

This study examines the effect of imiquimod (IMQ) on skin inflammation in humanized BRGSF mice boosted with human Flt3L. Although skin inflammation and epidermal thickening occurred, the response was mainly mediated by murine immune cells, with limited human immune cell activation.

Key outcome of the study

IMQ treatment induced skin inflammation characterized by epidermal thickening and immune cell infiltration. However, human immune cell activity remained limited, with the inflammatory response largely driven by the murine immune system.

Mouse model

BRGSF-HIS humanized mouse model developed by genOway, reconstituted with human CD34+ hematopoietic stem cells and boosted with human Flt3L to support human immune system engraftment.

TARGET:

Keywords

Psoriasis, Skin inflammation, Humanized models, Innate immunity, Flt3L boosting

Technical specifications

Humanized BRGSF-HIS mouse model, CD34+ HSC reconstitution, hFlt3L boost, IMQ topical treatment, Skin inflammation model

Related products

Catalogue product

genO‑BRGSF‑HIS

Customized product

No items found.